We first explored the mRNA expression of MCL1, SRC, and Cofilin1 (CFL1) across cancers in the TCGA and Australian Pancreatic Genome Initiative (APGI) to identify contexts where a dual MCL-1, and SRC inhibitor strategy may be effective. This evidence concerns the gene CFL1 and cancer.